Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133⁺ Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy

Figure 1

Manufacturing process from the drug substance to the medicinal product. The figure summarizes using a flowchart the entire process from the collection of the patient’s bone marrow to the injection of the medicinal product back to the patient.